BioTrinity - Keep me informed

BioTrinity - Keep me informed: One week left until BioTrinity 2009 - Record Partnering Activity

2009-03-26T12:40:39Z

One week until BioTrinity 2009

Record Partnering Activity Reported

It isn't too late to get involved in partnering at the biggest and best BioTrinity yet! With just a few days to go before BioTrinity 2009 can you afford to be missing from the list of nearly 300 companies already confirmed as attending from April 2-3 in Oxford?

We've seen a blitz in partnering activity, which has already outstripped previous years by 30% and with several hundred new partnering requests submitted each day, this record breaking growth keeps getting bigger.

There are just five working days left to register, including today, and although you can register in person on the morning of April 2 and all delegates can continue to make partnering requests during the conference - remember that the meeting schedules of the companies you wish to meet may become full.

BioTrinity 2009 Key Facts:

420 delegates already confirmed
290 companies already confirmed
Over 2500 of partnering requests already made (a new record)
Over 150 licensing opportunities
40 investors and financial institutions attending

If you haven't looked at the list of nearly 300 companies attending recently, here's 50 of the most recently confirmed:

Abbott Diagnostics Division
ACE BioSciences A/S (Denmark)
Animascope (France)
Apex Healthcare Consulting
BioFocus DPI
Biopta
Bristol-Myers Squibb Company
BTG International
CABI
Cambridge BioScience
Circassia
Cyprotex Discovery
Diamond Light Source
Entrepreneurs Fund LLP
ERT
e-Therapeutics plc
ETV Captial
Fulcrum Pharma
Fusion Antibodies
Genzyme
Glysure
Hybrid Systems
IDBS
Immatics Biotechnologies GmbH (Germany)
Intellihep
IQ Capital Partners LLP
Isis Innovation
NGN Capital (USA)
Nomura Code
Novolytics
OI Sciences
Oxford Cardiac Pharmacology
Oxford Technology Management
Oxitec
Pall Life Sciences
Patheon UK
Pfizer
PharmaTelevision
PiR Group
PRN Clinical Services
Queens University Belfast
Quintiles
Saretius
Shire
Solvias AG
Technomark Life Sciences
University of Bradford
University of Oxford
Vectus Biosystems Pty
Zein Biotec Plc

See who else is attending...

Today is the last day to let us know if you'll be joining the more than 120 other delegates confirmed for the Gala Dinner, although you've got until Friday to let us know about the pre-conference reception. Media coverage will include FT, Nature, PharmaProjects with live recording of interviews by Pharma TV on site.

Finally, we welcome your enquiries - do feel invited to call us on 01865 594640 to allow us to answer your queries or questions about BioTrinity 2009.

If you're seeking solutions to tough financing conundrums, choose BioTrinity 2009

...........................................................................................

What other people think:

"My first time at a UK partnering conference was BioTrinity 2008, and I did a deal with an NZ pharma as a direct result". Allen Hakimi, Managing Director at Technomark Life Sciences

"As a direct result of our focused partnering meetings we introduced proteros to potential clients at BioTrinity 2008 which we are pleased to report resulted in several new opportunities and one of which has developed into a substantial business relationship". Gordon J Woodrow, VP at Proteros biostructures GmbH

"...I would like to congratulate you on an excellent meeting.."
Tim Haines, Partner, Abingworth Management

"...Congratulations on such a good event. I had a very productive day with lots of organized and impromptu meetings - a very worthwhile event for me." Dr Charles Potter, CEO, Glide Pharma

Read more testimonials...

............................................................................................

Thanks to our Sponsors:

............................................................................................

BioTrinity is organised by OBN - Rapidly becoming the UK's leading biotech network

� 2006-2009 OBN

BioTrinity - Keep me informed: 9 Days to Go until BioTrinity - Choice of Ten Expert Workshops

2009-03-23T13:49:29Z

View this message in a browser

Expert Workshops at BioTrinity 2009

A record number of partnering requests have been made already at BioTrinity 2009, eclipsing last year with over a week to go. Although the partnering system will be active right up to and throughout the conference, if you leave it too late to get involved- you may find the people you want to meet have a full schedule.

Don't forget to book yourself into some of the ten expert workshops or social networking occasions available at BioTrinity 2009: the Gala Dinner and Pre-Conference Reception will be attended by a large number of R&D companies as well as a number of investors.

There is a diverse choice of excellent workshops that can be booked through the partnering system covering a panopoly of new topics including how Oxford spins out new life sciences companies, acquiring assets from distressed companies, EU rare disease policy, IP strategy and cost control, reimbursement and market access, retention, access to Welcome Trust funding, and opportunities for funding via the Innovative Medicines Initiative.

If you don't get a chance to sign up for workshops via the partnering system, you can still walk in to workshops on the day, but only if there are spaces available after pre-booked delegates have taken their seats. This is also the last call for bag inserts, whether they be promotional brochures or executive toys. See who is attending BioTrinity 2009.

...........................................................................................

Workshop Details:

Purchasing from distressed sellers - tips and traps

Host: Chris Shelley, Partner, Manches LLP

One man's misfortune is another man's fortune. While the current economic downturn may not be good news for some companies, it will also present opportunities for others with cash to spare and an eye for a bargain. However, if you are in a position to purchase assets from a company in distress, you will need to understand that the process is different from a normal transaction. You need to set your approach and expectations accordingly. In this workshop experts from our corporate, employment and intellectual property departments will take you through some of the tips and traps inherent in purchasing financially distressed businesses including managing transfer of risk, ownership of IP, supplier's retention of title claims, retaining leased equipment and use of premises and employment liabilities.

...........................................................................................

Spinning out the Oxford Way

Host: Sue Staunton, Partner, James Cowper and Linda Naylor, Head of Tech Transfer, Isis Innovation

Isis Innovation and James Cowper will discuss the methodologies for spinning out life science based businesses used by the University of Oxford�s technology transfer company.

...........................................................................................

Developments in EU Rare Disease Policy and implications for pipeline products

Host: Wills Hughes-Wilson, Senior Director, Health Policy Europe, Genzyme (US)

In the 10 years since the adoption of the EU�s Orphan Regulation the EU legislative framework has further evolved to take account of new technologies, including cell- and gene-therapies. Recent proposals for the creation of �National Plans� and further cooperation between Member States in sharing information to facilitate market access are also currently under discussion. Genzyme played a leading role in the creation of the EU�s orphan system and has continued to do so. The environment regulating pipeline products has become increasingly complex to navigate, but there is a pathway through.

...........................................................................................

How to streamline IP strategy for dual US and European patent protection and enforcement

Host: Dr Tony Maschio, Partner & Dr Kathleen Williams, Partner & Dr. Candi Soames, Partner, Edwards Angell Palmer & Dodge Innovations LLP

For the vast majority of biopharmaceutical companies, the US is the most important market in terms of potential sales, collaborations and sources of investment. Despite this, for most European companies, IP strategy is designed around a European model and does not take into consideration the particular requirements of US law. In this workshop, European patent attorneys Dr. Candi Soames and Dr. Tony Maschio, together with registered US patent attorney Dr. Kathleen Williams, will explain how to optimise European strategy to obtain the best advantage both in Europe and the US.

...........................................................................................

Patents in the credit crunch: keeping costs down

Hosts: Rebecca Tollervey & Simon Kiddle, Partners, Mewburn Ellis LLP

Working within an IP budget is always a challenge. There is an ongoing need to reduce costs while ensuring that valuable intellectual property is protected and the right expert advice is obtained. We will be discussing how costs can be kept down by careful filing strategies, and identifying points in the life of a patent where savings can be made.

...........................................................................................

Evaluating Innovative Technologies: Reimbursement and Market Access Planning

Host: Adam Barak, VP, Boston Healthcare Associates, Inc

For companies developing innovative technologies, it is essential to prepare to achieve payer endorsement as well as to secure the necessary licences which will enable them to launch their products in a given territory. Payers in all countries have been introducing various means of managing healthcare expenditures, and it therefore behoves a company hoping to secure payment for its technology to know what the payer�s expectations are in order for the technology to achieve reimbursement and enable optimal market access. Similarly, without knowing what the payers� expectations are, it is very difficult to derive what an optimal in-market price should be or what the international price range should be for the technology and therefore what its value is in terms of sales expectations or its acquisition potential. We will explain the steps and activities needed to determine how a company can evaluate what a technology�s price should be, how it can achieve reimbursement and how the value of the technology can be assessed and appraised.

...........................................................................................

How to retain and motivate key employees when finances are restricted

Host: Rod Cook, Partner, Biotech Personnel

There is clear evidence that redundancy programmes do not always produce the savings expected. Rod will draw on his experience of assisting clients with budget restrictions to discuss ways of either avoiding redundancies or minimising the impact. He will refer to data from the most comprehensive remuneration survey of the UK biotech industry.

...........................................................................................

Accelerated Process Integrated Drug Development

Host: Denis Geffroy, Almac

A new approach to early clinical development using our specialist technologies where appropriate e.g. Biocatalysis, Peptides, Solid State Services. A complete set of solutions aimed at accelerating entry into clinical development; saving on average 1 year from the early clinical development timelines. The RAPIDDTM package includes an integrated set of services (API, Drug Product, Pre-clinical tox and safety studies) speeding up entry into Phase I clinical trials (First in Man).

...........................................................................................

How to Access Wellcome Trust Translational Funding

Host: Richard Seabrook, Head of Business Development and Nick Dunster, Senior Business Analyst, The Wellcome Trust

Technology Transfer at the Wellcome Trust is a committed funder of translational research. Bridging the gap between fundamental medical research and commercial application, Technology Transfer supports both academic researchers and companies by funding applied research and development projects to a stage where they are attractive to a follow-on funder. At this workshop you will hear about R&D projects that have already been funded by the Wellcome Trust and, more importantly, how you can access translational funding to support your research.

...........................................................................................

The IMI opportunities for biotechnology companies

Host: Jackie Hunter, GSK and IMI board member

Jackie will outline the IMI and what opportunities are available for biotech companies to seek funding from the Innovative Medicines Initiative, from the expert perspective of an IMI board member.

...........................................................................................

Thursday 26th March is the last day you can sign up for the excellent Gala Dinner attended by more than 120 delegates, although you have until Monday 30th March to sign up for the Pre-Conference Networking Reception. Take a look at the social programme. Call the OBN office on 01865 594640 to book your choices.

............................................................................................

Thanks to our Sponsors:

............................................................................................

BioTrinity is organised by OBN - Rapidly becoming the UK's leading biotech network

� 2006-2009 OBN

BioTrinity - Keep me informed: Partnering surges at BioTrinity 2009 - just 10 working days left to register

2009-03-18T13:35:25Z

View this message in a browser

BioTrinity 2009: Two weeks left to register!

Pfizer is the latest of 13 global pharma companies to register for BioTrinity, sending a Senior Director from its Worldwide Licensing and Business Development Group. Find out which other global pharmas are coming to BioTrinity.

One-to-one meeting requests have surged in the last 24 hours, with literally hundreds of partnering requests made, with a great deal of interest generated by the more than 30 VC and investor delegates, and the excellent biotech and medtech companies which will deliver over thirty 8 minute partnering/corporate presentations on April 2-3. See who else is attending and find out whyBioTrinity has grown even in tough economic climes.

Don't miss out on the biggest and the best yet BioTrinity - in case you haven't seen the most recent agenda, here is a list of the expert panelists and hand-picked innovative and entrepreneurial companies who will be presenting:

Panelists and Chairpeople

Ken Powell, ex CEO, Arrow and Exec. Chairman, Q-Chip
Regina Hodits, Partner, Atlas Venture
Jane Dancer, Vice President Business development, Cellzome
Ian Nicholson, CEO, Chroma Therapeutics
Bruce Savage, CEO, CMP Therapeutics
Mike Wort, MD, De Facto Communications
Mark Ashton, COO, Evotec
David Knowles, Ex-CSO, ex Piramed and CSO of CellCentric
Allison Robbins, Senior Associate, Genzyme Ventures
Kate Burt, Director, Worldwide Transactions, GSK
Esteban Pombo-Villar, Head of Strategic Alliance management, Novartis Institutes of BioMedical Research
Martin Edwards, Senior Partner, Novo Ventures
Anker Lundemose, MD, President, OSI Prosidion
David Mott, Investment Director, Oxford Capital Partners
David Laskow-Pooley, MD, Pharmafor
Fintan Walton, CEO, PharmaVentures
Sam Fazeli, Head of European Equity Research, Piper Jaffray
Nigel Sheail, VP, Global Head of Licensing & Pharma Patnering, Roche
Graeme Martin, President & CEO, Takeda Research Investment, Inc
John Burt, CEO, Thiakis

Company Showcase Speakers

James Noble, CEO, Adaptimmune
Denis Geffroy, Senior Business Manager, Almac Sciences
Keith F Martin, CEO, Apitope
Nigel Parkinson, Account Manager, Aptuit
Andrew Kelly, CSO, Biotecnol
Melanie McCullagh, Director Business Development, Biotica
Chris Atterwill, Scientific And Business Advisor To Capsant, Capsant Neurotechnologies
Nick La Thangue, Founding Director, Celleron Therapeutics
Charles Swingland, Deputy Chairman, Circassia
Paul Davies, CEO, Cytox Group
Eddy Littler, CEO, Domainex
Malcolm Young, CEO, e-Therapeutics plc
Mark Ashton, Executive Vice President, Evotec
Paul Murphy, CEO, Eykona Technologies
Paul Drohan, VP & General Manger, Genzyme UK & Ireland
Simon Jones, Business Development Director, Gilde Pharma
David Scales, CEO, Glycoform
Chris Jones, CEO, Glysure
Malcolm, Weir, CEO, Heptares
John Beadle, Chairman, Hybrid Systems
Carlton Brown, CEO, Immune Targeting Systems
James Noble, CEO, Immunocore
Chris Ullman, CSO, Isogenica
Andrew Lane, MD, MorphoSys
Thomas A. Weaver, Director, MRC Harwell
Nick Housby, CSO, Novolytics
Nick Skaer, CEO, Orthox
John Dawson, CEO, Oxford BioMedica
Richard Broadhead, CEO, Oxford Expression Technologies
Mike Evans, CEO, Oxford Gene Technology
Peter Friend, Director of the Oxford Transplant Centre and Clinical Trial Service Unit
Hadyn Parry, CEO, Oxitec
Christophe Chassagnole, COO, Physiomics Plc
Keith Powell, CEO, Polytherics
Robin Quirk, COO,Director, RegenTec
Wolfgang Edenbeck, Head of Fluorine Team, Saltigo
David Colpman, VP, Shire
Charlie Alexander, Senior Business Development Manager, Shire
Alasdair Naylor, Head of Research, Solace Pharmaceuticals

Finally, Thursday 26th March is the last day you can sign up to join over 100 fellow delegates for the excellent Gala Dinner or the BioTrinity Golf Tournament, although you have until Monday 30th March to sign up for the Pre-conference Networking Reception. Take a look at the social programme.

Among the 500 delegates expected, there will be delegates from 15 countries will be present, and 35 corporate presentations will be heard from companies selected from the Oxford BioCluster, as well as London, Cambridge as well as Bristol, Southampton, Kent, Nottingham, Manchester and Newcastle, making BioTrinity a veritable UK Biotechnology Showcase.

...........................................................................................

What other people think:

"My first time at a UK partnering conference was BioTrinity 2008, and I did a deal with an NZ pharma as a direct result". Allen Hakimi, Managing Director at Technomark Life Sciences

"...I would like to congratulate you on an excellent meeting.."
Tim Haines, Partner, Abingworth Management

"...Congratulations on such a good event. I had a very productive day with lots of organized and impromptu meetings - a very worthwhile event for me." Dr Charles Potter, CEO, Glide Pharma

Read more testimonials...

............................................................................................

Thanks to our Sponsors:

............................................................................................

BioTrinity is organised by OBN - Rapidly becoming the UK's leading biotech network

� 2006-2009 OBN

BioTrinity - Keep me informed Partnering surges at BioTrinity 2009 - just 10 working days left to register

2009-03-18T13:33:02Z

View this message in a browser

BioTrinity 2009: Two weeks left to register!

Panelists and Chairpeople

Company Showcase Speakers

...........................................................................................

What other people think:

"My first time at a UK partnering conference was BioTrinity 2008, and I did a deal with an NZ pharma as a direct result". Allen Hakimi, Managing Director at Technomark Life Sciences

"...I would like to congratulate you on an excellent meeting.."
Tim Haines, Partner, Abingworth Management

"...Congratulations on such a good event. I had a very productive day with lots of organized and impromptu meetings - a very worthwhile event for me." Dr Charles Potter, CEO, Glide Pharma

Read more testimonials...

............................................................................................

Thanks to our Sponsors:

............................................................................................

BioTrinity is organised by OBN - Rapidly becoming the UK's leading biotech network

� 2006-2009 OBN

BioTrinity - Keep me informed: Do you know which 35 investors are partnering at BioTrinity 2009?

2009-03-11T15:42:12Z

View this message in a browser

Record Number of Investors at BioTrinity 2009

If you are seeking financing in the next one to two years, or if you have a colleague or client seeking financing - it may well be worth making sure that BioTrinity 2009 is on the radar given our growing roll call of senior international investors attending on April 2nd and 3rd:

Abingworth Management (Principal)
Advent Venture Partners (Principal)
Albion Ventures LLP (Director)
Andy Richards (Serial Entrepreneur)
Atlas Venture (Partner and Analyst)
Avlar BioVentures (CEO)
BSI SA (Chief Investment Officer, VP, Private Equity, Italy)
Canaccord Adams (MD)
Edmond de Rothschild Investment Partners (Partner, France)
Entrepreneurs Fund LLP (Associate)
Esperante Ventures (MD, Netherlands)
ETV Capital (Deal Executive)
Excalibur Group (Investment Director, formerly Merlin Biosciences)
Forbion Capital Partners (Principal)
Genzyme Ventures (Associate)
H2O Venture Partners (Co-founder and CEO)
IP Group plc (Client Services Manager)
Ipso Ventures (Executive Director)
IQ Capital (Managing Partner, Co-founder)
Mercia Technology Seed Fund (Principal)
MP Healthcare Venture Management (VP, USA)
MVM Life Science Partners (Finance Director)
Nomura Code Securities (Director, Corporate Finance)
Novo A/S (Senior Partner, Denmark)
Orion Healthcare Equity Partners (Partner)
Oxford Capital Partners (Investment Director and Investment Manager)
Oxford Technology Management (Founder, MD and Seed Capital Team)
Piper Jaffray (Head of European Equity Research)
Rainbow Seed Fund (Investment Manager)
Seraphim Capital (General Partner)
Seroba Kernel (Partner, Ireland)
SPARK Ventures (Investment Director)
SR One (General Partner, USA)
Takeda Research Investment, Inc (President & CEO, USA)
The Wellcome Trust (Head of Business Development)

See who else is attending...

These investors cover the breadth of life sciences investment, from biotech, to medtech and diagnostics, at all stages, from seed to late-stage. BioTrinity 2009 will also deal with the new reality of biotech and medtech finance in our Investor Panel Discussion, analysing trends and dealing with a few current myths. This panel features Dr. Regina Hodits, Partner at Atlas Venture, Martin Edwards, Senior Partner at Novo A/S, Graeme R Martin Ph.D., President & CEO of TRI, Allison Robbins, Senior Associate at Genzyme Ventures, Sam Fazeli PhD, Head of European Equity Research at Piper Jaffray, and David Mott, Investment Director Oxford Capital Partners.

Given the tough economic climate of 2009, we have strived to provide the largest number of VCs and other investors possible at BioTrinity 2009, tripling the number of investors attending, a transformation we intend to repeat at BioTrinity 2010.

Among the 500-600 expected, there will be delegates from 15 countries will be present, and 35 corporate presentations will be heard from companies selected from Oxford, London, Cambridge as well as Bristol, Southampton, Kent, Nottingham, Manchester and Newcastle, making BioTrinity a veritable UK Biotechnology Showcase. The latest addition to this is Heptares Therapeutics, which just completed a �21m funding round.

If you're seeking solutions to tough financing conundrums, choose BioTrinity 2009

...........................................................................................

What other people think:

"My first time at a UK partnering conference was BioTrinity 2008, and I did a deal with an NZ pharma as a direct result". Allen Hakimi, Managing Director at Technomark Life Sciences

"...I would like to congratulate you on an excellent meeting.."
Tim Haines, Partner, Abingworth Management

"...Congratulations on such a good event. I had a very productive day with lots of organized and impromptu meetings - a very worthwhile event for me." Dr Charles Potter, CEO, Glide Pharma

Read more testimonials...

............................................................................................

Thanks to our Sponsors:

............................................................................................

BioTrinity is organised by OBN - Rapidly becoming the UK's leading biotech network

� 2006-2009 OBN

BioTrinity - Keep me informed Record Registrations - Only Four Weeks Left to Register (Partnering is Live)

2009-03-03T16:50:08Z

View this message in a browser

Record Registrations for BioTrinity 2009 (April 2-3)

UK's Premier Biotechnology and Investment Conference

Click here to register

Registrations for BioTrinity 2009 have surged in recent weeks, and we're delighted to announce record registration levels are 50% higher than last year. With four weeks to go, the UK's Premier Biotech and Investment Conference boasts the participation of thirty VCs and investors with over $33bn under management among more than 230 companies confirmed as participating. 60% of the top 20 global pharma now have senior licensing presence confirmed including AstraZeneca, Roche, Novartis, Eli Lilly and GSK.

Five key facts about BioTrinity 2009 - Oxford

12 of world's top 20 global pharma represented
230 companies already confirmed from 14 countries
Partnering is live and uniquely takes place in private rooms
Gala Dinner at an Oxford College
30 VCs and Investors already confirmed

For the first time, BioTrinity 2009 will be opened by Lord Davies of Abersoch CBE, the Minister of State for Trade and Investment at DBERR and the FCO, who will be discussing how the UK government will be fighting the economic challenges facing our industry.

Also for the first time, BioTrinity 2009 will also feature plenaries and panel discussions involving some of Oxford's most successful entrepreneurs Ian Nicholson, Bryan Morton, Anker Lundemose and Bruce Savage, as well as the entrpreneurs John Burt, David Knowles and Ken Powell drawn from across the UK who have returned nearly $500m of value to their investors.

35 corporate presentations will be made by companies selected from Oxford, London, Cambridge as well as Bristol, Southampton, Kent, Nottingham, Manchester and Newcastle, making BioTrinity a UK Biotechnology Showcase. The latest addition is Heptares Therapeutics, which just completed a �21m funding round.

In yet another first, BioTrinity 2009 will feature live recording of interviews by PharmaTV adjacent to the main networking hub, so if you want to appear on the groundbreaking online TV channel for the biopharma industry, make sure you are in Oxford from April 2-3, 2009.

BioTrinity unites the UK�s biotech industry, and provides an ideal platform to meet with pharma, investors and biotech companies in the most beautiful city in England, just 1 hours' drive from Heathrow International Airport. The updated programme for BioTrinity has been published online and can be downloaded.

...........................................................................................

Is your company missing from the list of companies attending BioTrinity 2009?

AstraZeneca	Bristol Myers-Squibb	Eli Lilly
Genzyme	GSK	Merck
Novartis	(OSI) Pharmaceuticals	Roche
Shire Pharma	Takeda	Teva Pharma
Abingworth Mgmt	EUSA Pharma	Atlas Venture
Albion Ventures	Andy Richards	Avlar BioVentures
BSI SA	Advent Venture Partners	Canaccord Adams
Excalibur Group	ETV Capital	Esperante Ventures
Edmond de Rothschld Invest	Forbion Capital Partners	H2O Venture Partners
Genzyme Ventures	H2O Venture Partners	Mercia Tech. Seed Fund
MPHVM	MVM Life Science	Nomura Code Securities
Novo A/S	Oxford Capital Partners	Orion Healthcare Equity
Oxford Tech. Management	Rainbow Seed Fund	Piper Jaffray
Rosetta Capital	SPARK Ventures	SR One
Takeda Research Investment	The Wellcome Trust	AbD Serotec
AdaptImmune	Alchemy Healthcare	Allergan
Almac Sciences	Apitope	Apex Healthcare Consulting
Aptuit	AS-Tec Chemicals	ATP Bio
Avecia Biologics	BASi	BBSRC
Bench International	BigDNA	BioCentrum (Poland)
BioCentury	BioConnection B.V.	BioDundee
Bioedge Pharma	Biomaterials & Tissue Engineering Centre	BioPark
Biotech Personnel	Biotecnol S.A.	Biotica
BioUETIKON (Ireland)	Bodium Consulting	Bridgehead International
CABI	CML Europe	Cancer Research UK
Canaccord Adams	Caprotec Bioanalytics GmbH	Capsant
Carbogen Amcis AG	Catalent Pharma Solutions	CellCentric
Celleron Therapeutics	Cellvax (France)	Cellzome
Charles Russell LLP	Chroma Therapeutics	Circassia
CellCentric	CLS Communication	CMP Therapeutics
CMS Cameron McKenna	Cognitive Drug Research	Comm. Strat. Group, Inc
Covance Laboratories	CureVac (Germany)	Cytox Group
D2M	D Young & Co.	De Facto Communications
Debiopharm SA (Switz)	Domainex	Drug Discovery Today (media)
Drug Intelligence	EAPD Innovations	EBD Group, Inc.
Eczacibasi Pharma (Turkey)	Epistem	e-Therapeutics plc
ETV Capital	Eviva Pharma	Evotec
Eykona Technologies	FOCUS Insurance	FP7
Frank B Dehn	Fry Heath Spence	Fulcrum Pharma
Fusion IP plc	Genzyme	Genzyme Ventures (US)
George James ltd	Giles Insurance Brokers	Glide Pharma
GlycoForm	Glysure	Haemostatix
Health Protection Agency	Heptares	High Commission of Canada
Hybrid Systems	Immune Targeting Systems	Immunocore
IMS Health (media)	Inhibox	Inst. Pharma Innovation
Interea International	International LabMate	Intertek
Isaac & Co	Ithaka Life Sciences	J A Kemp & Co
James Cowper	KWS BioTest	Lab Support UK Ltd
Life Scientific (Ireland)	Manches LLP	MEPC Milton Park
Mewburn Ellis LLP	Mitsui & Co Europe	MorphoSys UK
MRC Harwell	Morrison & Foerster	M-Scan
NDA Analytics	Netherlands FIA	Niche Science & Technology
Nightingale Associates	Novasep Synthesis	Novolytics
O2H	OBN	OctoPlus N.V. (Netherlands)
OI Sciences	Orthox	Oxford BioMedica
Oxford Expression Tech.	Oxford Gene Technology	Oxford Science Park
Oxford Transplant Centre	Oxitec	Particle Therapeutics
Penn Pharma	Pharmaceutical Profiles	PharmaFor
PharmaLinks	PharmaTV	PharmaProjects
PharmaVentures	Pharmidex	Pharminox
Physiomics plc	Pinnacle Associates	PiR Interims
Plant Vaccines Limited	Polytherics	ProPharma Partners
Protherics, A BTG Company	PULSE Scientific	Reed Scientific
RegenTec	Regulatory Resources Group	Riverbank IT Management
RSSL Pharma	RUSSLAN Clinical Research	Ruston Poole International
Saint Malo Agglomeration	Saltigo	SCRIP
SEHTA	Selcia	Simbec Research
Solace Pharma	Sochinaz / Bachem	Solvias AG (Switzerland)
SP Industries	Steve D Young & Co	Summit plc
SynCo Bio Partners B.V.	Syntagon (Sweden)	Syntaxin
Synth-Isis	Talentmark	Technomark Life Sciences
Tepnel	Thermal Transfer	Therabel Europe (Ireland)
ThermoFisher Scientific	Thiakis (now part of Wyeth)	TNO Quality of Life
TVLSN	Ubichem Plc	UK Trade and Investment
UniTech Pharma (Sweden)	Universit� Libre de Bruxelles	Univ. Manc. Incubtor Co.
Univ. of Manchester IP	VirdisPharma	Wragge & Co LLP

See who else is attending...

...........................................................................................

What other people think:

"My first time at a UK partnering conference was BioTrinity 2008, and I did a deal with an NZ pharma as a direct result". Allen Hakimi, Managing Director at Technomark Life Sciences

"...I would like to congratulate you on an excellent meeting.."
Tim Haines, Partner, Abingworth Management

"...Congratulations on such a good event. I had a very productive day with lots of organized and impromptu meetings - a very worthwhile event for me." Dr Charles Potter, CEO, Glide Pharma

Read more testimonials...

............................................................................................

Thanks to our Sponsors:

............................................................................................

BioTrinity is organised by OBN - Rapidly becoming the UK's leading biotech network

� 2006-2009 OBN

BioTrinity - Keep me informed $32bn Under Management - Meet Life Science VCs at BioTrinity 2009

2009-02-23T11:19:24Z

View this message in a browser

BioTrinity 2009 - Oxford, April 2-3, 2009

UK's Premier Biotechnology and Investment Conference

Click here to register

Over 50 biotech and medtech investors from the US and Europe will be partnering at BioTrinity 2009 Oxford (April 2-3), including some of the biggest names in the industry: Atlas, Abingworth, Avlar, MVM, and Excalibur and corporate venturers such as GSK’s SR One, Novo A/S, Genzyme Ventures, Takeda Research Investments, and MPHVM. Early stage investors Spark, Esperante, Rainbow, Oxford Capital and Oxford Technology will also be in force meeting start-ups, as well as the newly formed Albion Ventures LLP. Investors attending have a total of $32bn under management.

Four key facts about BioTrinity 2009 - Oxford

10 of world's top 20 global pharma represented
200 companies already confirmed from 12 countries
Partnering is live and takes place in private rooms
Gala Dinner at an Oxford University College

BioTrinity 2009 will also feature plenaries and panel discussions from the successful entrpreneurs John Burt, David Knowles and Ken Powell who built up and sold UK biotechnology companies Thiakis, Piramed and Arrow and returned nearly $500m of value to their investors.

BioTrinity 2009 will face the challenges of the current climate head-on with key issues addressed by industry leaders. Dealing with successful deal making in the current climate, BioTrinity will draw on the experiences of key industry pharma licensing figures, including Nigel Sheail, VP Global Head of Licensing at Roche, Esteban Pombo-Villar, Head of Strategic Alliance Management at Novartis and Kate Burt, Director, Transactions at GSK, as well as Ian Nicholson, CEO of Chroma Therapeutics and Jane Dancer, Vice President Business Development at Cellzome.

Dealing with successful fundraising in the current climate, BioTrinity will draw on the experiences of key VCs including Regina Hodits, Partner at Atlas Venture, which recently closed its $283m Fund VIII, as well as corporate venturers Graeme R Martin, CEO, Takeda Research Investments, Martin Edwards, Senior Partner, Novo A/S, Allison Robbins, Senior Associate, Genzyme Ventures, Sam Fazelli, Head of European Equity Research, Piper Jaffray and David Mott, Investment Director at Oxford Capital Partners who will be among over 50 investor delegates expected to attend this year.

BioTrinity unites the UK’s biotech industry, and provides an ideal platform for US and European companies to partner with pharma, meet investors and European companies in the most beautiful city in England, just 1 hours' drive from Heathrow International Airport. The updated programme for BioTrinity has now been published online and can be downloaded: online

...........................................................................................

Who else is attending BioTrinity 2009?

GSK	Novartis	Merck
Roche	Genzyme	Bristol Myers-Squibb
Eli Lilly	Takeda	Shire Pharma
Teva Pharma	(OSI) Pharmaceuticals	EUSA Pharma
Abingworth Mgmt	Esperante Ventures	Takeda Research Inv., Inc.
Novo A/S	Atlas Venture	MPHVM
SR One	Excalibur Group	H2O Venture Partners
Oxford Capital Partners	Oxford Tech. Management	Piper Jaffray
H2O Venture Partners	Genzyme Ventures	Avlar BioVentures
MVM Life Science Prtnrs.	Andy Richards	The Wellcome Trust
Rainbow Seed Fund	Albion Ventures	SPARK Ventures
ETV Capital	Edmond de Rothschld Inv Prt	Orion Healthcare Equity

See who else is attending...

...........................................................................................

What other people think:

"My first time at a UK partnering conference was BioTrinity 2008, and I did a deal with an NZ pharma as a direct result". Allen Hakimi, Managing Director at Technomark Life Sciences

"...I would like to congratulate you on an excellent meeting.."
Tim Haines, Partner, Abingworth Management

"...Congratulations on such a good event. I had a very productive day with lots of organized and impromptu meetings - a very worthwhile event for me." Dr Charles Potter, CEO, Glide Pharma

Read more testimonials...

............................................................................................

BioTrinity is organised by OBN - Rapidly becoming the UK's leading biotech network

BioTrinity - Keep me informed Key Industry Issues Dealt with at BioTrinity 2009

2009-02-10T18:24:12Z

View this message in a browser

Key Industry Issues Dealt with at BioTrinity

The UK's Premier Biotech and Investment conference will feature plenaries and panel discussions from the successful entrpreneurs John Burt, David Knowles and Ken Powell who built up and sold UK biotechnology companies Thiakis, Piramed and Arrow and returned nearly $500m of value to their investors.

BioTrinity 2009 will face the challenges of the current climate head-on with key issues addressed by industry leaders. Dealing with successful deal making in the current climate, BioTrinity will draw on the experiences of key industry pharma licensing figures, including Nigel Sheail, VP Global Head of Licensing, Roche, Esteban Pombo-Villar, Head of Strategic Alliance Management, Novartis Institutes of BioMedical Research and Kate Burt, Director, Transactions, GSK.

Dealing with successful fundraising in the current climate, BioTrinity will draw on the experiences of key VCs including Regina Hodits, Partner at Atlas Venture, which recently closed its $283m Fund VIII, as well as corporate venturers Graeme R Martin, CEO, Takeda Research Investments, Martin Edwards, Senior Partner, Novo A/S, Allison Robbins, Senior Associate, Genzyme Ventures, Sam Fazelli, Head of European Equity Research, Piper Jaffray and David Mott, Investment Director at Oxford Capital Partners who will be among over 50 investor delegates expected to attend this year.

There are just a few days left to register at the Special Rate, and you will be able to start requesting meetings when the partnering meeting is activated in a few days time.

Download the BioTrinity 2009 - Preliminary Programme - Now Available!

Who else is attending BioTrinity 2009?

GSK	Novartis	Merck
Roche	Genzyme	Bristol Myers-Squibb
Eli Lilly	Takeda	Shire Pharma
Teva Pharma	(OSI) Pharmaceuticals	EUSA Pharma
Abingworth Management	Atlas Venture	TRI, Inc.
Novo Ventures	Esperante Ventures	MPHVM
SR One	Excalibur Capital	H2O Venture Partners
Oxford Capital Partners	Oxford Tech. Management	Piper Jaffray
H2O Venture Partners	Andy Richards	MVM Life Science Partners
Avlar BioVentures	Genzyme Ventures	The Wellcome Trust
Syntaxin	Vantia Therapeutics	Thiakis
Domainex	Immunocore	Chroma Therapeutics
Cytox Group	Eykona Technologies	Solvias AG
GlycoForm	Oxford Gene Technology	AbD Serotec
Epistem	Circassia	ProPharma Partners
Capsant	Apitope	Aptuit
Simbec Research	Particle Therapeutics	Debiopharm SA
Regulatory Resources Group	Glide Pharma	Epistem
Inhibox	Oxford BioMedica	Hybrid Systems
UniTech Pharma	Cellzome	Covance Labs
Drug Intelligence	Tepnel	Intertek
Catalent Pharma	Saltigo	BBSRC
Oxitec	Ithaka Life Sciences	RSSL Pharma
ThermoFisher	Oxford Transplant Centre	Canadian High Commission
Technomark LS	PharmaVentures	VirdisPharma
MorphoSys UK	Niche Science & Technology	PULSE Scientific
Cancer Research UK	OctoPlus N.V	Gray Institute
Cambridge Major Labs	TNO Quality of Life	OET
AdaptImmune	Evotec	BioUETIKON
Novasep Synthesis	Eczacibasi Pharma	UKTI
Pharmaceutical Profiles	Orthox	Life Scientific
De Facto Communications	Cognitive Drug Research	MEPC Milton Park
EAPD Innovations	Carbogen Amcis AG	Manches LLP
Novolytics	Physiomics plc	Alchemy Healthcare
Oxygen Healthcare	Synth-Isis	PVL
Summit plc	PiR Interims	EBD Group, Inc.
BioConnection B.V.	Arrow Therapeutics	PharmaTV
CMP Therapeutics	CureVac	Univ. Manchester IP
BioCentury	Drug Discovery Today	SCRIP

WHO SHOULD ATTEND?

Biotech & MedTech Executives

8 minute presentation opportunity to pharma and investor audience
Panel discussions for emerging biotechs on finance and key issues
Private 1-to-1 partnering rooms and booths

Mid & Large Pharma Executives

Access to Company presentations (Biotech and Medtech)
Private 1-to-1 partnering rooms and booths
Opportunity for dedicated partnering rooms

Investors

Invitation-only investor dinner
Wide range of investment opportunities
Private 1-to-1 partnering rooms
Opportunity for dedicated partnering rooms

Registration Fees

Register now online at www.biotrinity.com to take advantage of the Special rate offer which expires at 17.00 GMT February 17th 2008.

OBN Member companies can take advantage of the lower rate of �449 + VAT, including a complimentary ticket with the first person registering from within Full Member companies. Do consider registering early to ensure your partnering profile is available when partnering begins on February 17th 2009.

Are you ready to join the 350+ companies expected at BioTrinity 2009?

Special Registration Fee (until Feb 17, 2009)

Registration Fee (until April 1, 2009)

On-site Registration Fee

�549 + VAT

�599 + VAT

�650 + VAT

Contact Us

You are welcome to contact the organisers office at OBN with your registration queries or questions, whatever their nature.

Hilary Boardman, Events Manager, OBN
+44(0) 1865 594644
hilary.boardman@obn.org.uk

BioTrinity - Keep me informed Preliminary Programme Released

2009-02-02T22:47:38Z

View this message in a browser

BioTrinity Preliminary Programme Released

Registrations for BioTrinity 2009 are running nearly 3-fold higher than last year. The UK's Premier Biotech and Investment conference will feature plenaries and panel discussions from the successful entrpreneurs who built up Thiakis, Piramed and Arrow for acquisition, a hand-picked crop of over 30 company showcase presentations taking you from concept to patient, and representation from key global pharma licensing professionals available via our gold standard private partnering system. There are just 10 days left to register at the Special Rate.

Download the BioTrinity 2009 - Preliminary Programme - Now Available!

Who else is attending BioTrinity 2009?

GSK	Novartis	Merck
Roche	Genzyme	Bristol Myers-Squibb
Eli Lilly	Takeda	Shire Pharma
Teva Pharma	(OSI) Pharmaceuticals	EUSA Pharma
Abingworth Management	Atlas Venture	TRI, Inc.
Novo Ventures	Innovator Capital	MPHVM
SR One	Excalibur Capital	H2O Venture Partners
Oxford Capital Partners	Oxford Tech. Management	Piper Jaffray
Syntaxin	Vantia Therapeutics	Thiakis
Domainex	Immunocore	Chroma Therapeutics
Cytox Group	Eykona Technologies	Solvias AG
GlycoForm	Oxford Gene Technology	AbD Serotec
Epistem	Circassia	The Wellcome Trust
Capsant	Apitope	Aptuit
Simbec Research	Particle Therapeutics	Debiopharm SA
Regulatory Resources Group	Glide Pharma	Epistem
Inhibox	Oxford BioMedica	Hybrid Systems
UniTech Pharma	Cellzome	Covance Labs
Drug Intelligence	Tepnel	Intertek
Catalent Pharma	Saltigo	BBSRC
Oxitec	Ithaka Life Sciences	RSSL Pharma
ThermoFisher	Oxford Transplant Centre	Canadian High Commission
Technomark LS	PharmaVentures	VirdisPharma
MorphoSys UK	Niche Science & Technology	PULSE Scientific
Cancer Research UK	OctoPlus N.V	Gray Institute
Cambridge Major Labs	TNO Quality of Life	OET
AdaptImmune	Evotec	BioUETIKON
Novasep Synthesis	Eczacibasi Pharma	UKTI
Pharmaceutical Profiles	Orthox	Life Scientific
De Facto Communications	Cognitive Drug Research	MEPC Milton Park
EAPD Innovations	Carbogen Amcis AG	Manches LLP
Novolytics	Physiomics plc	Alchemy Healthcare
Oxygen Healthcare	Synth-Isis	PVL
Summit plc	PiR Interims	EBD Group, Inc.
BioConnection B.V.	Arrow Therapeutics	PharmaTV
CMP Therapeutics	CureVac	Univ. Manchester IP
BioCentury	Drug Discovery Today	SCRIP

WHO SHOULD ATTEND?

Biotech & MedTech Executives

8 minute presentation opportunity to pharma and investor audience
Panel discussions for emerging biotechs on finance and key issues
Private 1-to-1 partnering rooms and booths

Mid & Large Pharma Executives

Access to Company presentations (Biotech and Medtech)
Private 1-to-1 partnering rooms and booths
Opportunity for dedicated partnering rooms

Investors

Invitation-only investor dinner
Wide range of investment opportunities
Private 1-to-1 partnering rooms
Opportunity for dedicated partnering rooms

Registration Fees

Register now online at www.biotrinity.com to take advantage of the Special rate offer which expires at 17.00 GMT February 14th 2008.

Are you ready to join the 350+ companies expected at BioTrinity 2009?

Special Registration Fee (until Feb 14, 2009)

Registration Fee (until April 1, 2009)

On-site Registration Fee

�549 + VAT

�599 + VAT

�650 + VAT

Contact Us

You are welcome to contact the organisers office at OBN with your registration queries or questions, whatever their nature.

Hilary Boardman, Events Manager, OBN
+44(0) 1865 594644
hilary.boardman@obn.org.uk

BioTrinity - Keep me informed Message

2009-02-02T22:46:20Z

View this message in a browser

BioTrinity Preliminary Programme Released

Download the BioTrinity 2009 - Preliminary Programme - Now Available!

Who else is attending BioTrinity 2009?

GSK	Novartis	Merck
Roche	Genzyme	Bristol Myers-Squibb
Eli Lilly	Takeda	Shire Pharma
Teva Pharma	(OSI) Pharmaceuticals	EUSA Pharma
Abingworth Management	Atlas Venture	TRI, Inc.
Novo Ventures	Innovator Capital	MPHVM
SR One	Excalibur Capital	H2O Venture Partners
Oxford Capital Partners	Oxford Tech. Management	Piper Jaffray
Syntaxin	Vantia Therapeutics	Thiakis
Domainex	Immunocore	Chroma Therapeutics
Cytox Group	Eykona Technologies	Solvias AG
GlycoForm	Oxford Gene Technology	AbD Serotec
Epistem	Circassia	The Wellcome Trust
Capsant	Apitope	Aptuit
Simbec Research	Particle Therapeutics	Debiopharm SA
Regulatory Resources Group	Glide Pharma	Epistem
Inhibox	Oxford BioMedica	Hybrid Systems
UniTech Pharma	Cellzome	Covance Labs
Drug Intelligence	Tepnel	Intertek
Catalent Pharma	Saltigo	BBSRC
Oxitec	Ithaka Life Sciences	RSSL Pharma
ThermoFisher	Oxford Transplant Centre	Canadian High Commission
Technomark LS	PharmaVentures	VirdisPharma
MorphoSys UK	Niche Science & Technology	PULSE Scientific
Cancer Research UK	OctoPlus N.V	Gray Institute
Cambridge Major Labs	TNO Quality of Life	OET
AdaptImmune	Evotec	BioUETIKON
Novasep Synthesis	Eczacibasi Pharma	UKTI
Pharmaceutical Profiles	Orthox	Life Scientific
De Facto Communications	Cognitive Drug Research	MEPC Milton Park
EAPD Innovations	Carbogen Amcis AG	Manches LLP
Novolytics	Physiomics plc	Alchemy Healthcare
Oxygen Healthcare	Synth-Isis	PVL
Summit plc	PiR Interims	EBD Group, Inc.
BioConnection B.V.	Arrow Therapeutics	PharmaTV
CMP Therapeutics	CureVac	Univ. Manchester IP
BioCentury	Drug Discovery Today	SCRIP

WHO SHOULD ATTEND?

Biotech & MedTech Executives

8 minute presentation opportunity to pharma and investor audience
Panel discussions for emerging biotechs on finance and key issues
Private 1-to-1 partnering rooms and booths

Mid & Large Pharma Executives

Access to Company presentations (Biotech and Medtech)
Private 1-to-1 partnering rooms and booths
Opportunity for dedicated partnering rooms

Investors

Invitation-only investor dinner
Wide range of investment opportunities
Private 1-to-1 partnering rooms
Opportunity for dedicated partnering rooms

Registration Fees

Register now online at www.biotrinity.com to take advantage of the Special rate offer which expires at 17.00 GMT February 14th 2008.

Are you ready to join the 350+ companies expected at BioTrinity 2009?

Special Registration Fee (until Feb 14, 2009)

Registration Fee (until April 1, 2009)

On-site Registration Fee

�549 + VAT

�599 + VAT

�650 + VAT

Contact Us

You are welcome to contact the organisers office at OBN with your registration queries or questions, whatever their nature.

Hilary Boardman, Events Manager, OBN
+44(0) 1865 594644
hilary.boardman@obn.org.uk

Innovators and 2008 Fundraisers Featured Among Presenters at BioTrinity 2009

2008-12-01T17:59:56Z

I'm really pleased to be able to tell you that we've assembled a fantastic preliminary line-up at BioTrinity 2009, well in advance of what promises to be the UK's Premier Biotech and Investment Conference.

A brief look at the preliminary line up of the first 20+ companies selected for corporate presentations at the upcoming BioTrinity 2009 conference (April 2-3, Oxford), tells the exciting story of some of the most successful emerging and growing biotech and medtech companies in the world - some raising money in 2008. No wonder that registration for 2009 is running 3-fold higher than last year!

Vantia Therapeutics, which raised �19m earlier this year as it spun-out of Ferring Pharma ... more...

AdaptImmune, which hit the headlines with its engineered HIV killer T-cells 2 weeks ago ... more...

Circassia, which raised �11m in its oversubscribed round earlier this year, for immune control technologies ... more...

Apitope, which recently raised EUR 10m in a novel series A financing, to develop MS, diabetes and Factor VIII resistance treatments and diagnostics ... more...

Oxford BioMedica which has promising results with its ProSavin treatment for Parkinsons in phase I/II ... more...

EUSA Pharma which has raised over $295m in 24 months building its speciality pharma business ... more...

We'll also feature university spin-outs such as InhibOx, Cytox, Orthox, Particle Therapeutics and Novolytics. Take a look at the Company Showcase line-up as it begins to develop.

If your R&D company wishes to be considered for selection for one of the few remaining presentation slots, please make an online application or contact Jon Rees directly on +44(0)1865594642

Remember: You have just 10 days left to take advantage of the Early Bird registration offer.

New for 2009:

Invitation only Investor Dinner
Pre-conference champagne reception and Gala Dinner at Oxford colleges
Investment/corporate presentations
by biotech and medtech companies
Dedicated investment and partnering booths
Expanded networking space

Facts from 2008:

500+ one-to-one partnering meetings
400+ delegates
270 companies
12 countries represented

Companies already confirmed for 2009:

Shire Pharma Oxford BioMedica Merck AdaptImmune Eli Lilly Solvias AG Genzyme PharmaTV Bristol Myers-Squibb Intertek (OSI) Prosidion Oxygen Healthcare EUSA Pharma BBSRC Atlas Venture Domainex Takeda Research Investment Inc Hybrid Systems Novo Ventures Innovator Capital MP Healthcare Venture Management Oxford Capital Partners Vantia Therapeutics UniTech Pharma Immunocore Cytox Group Cellzome Eykona Technologies Oxford Gene Technology Plant Vaccines Limited Circassia Alchemy Healthcare GlycoForm Oxford Expression Technologies Glide Pharma Epistem Inhibox Capsant Neurotechnologies Orthox Giles Insurance Apitope Simbec Research Particle Therapeutics Regulatory Resources Group De Facto AbD Serotec Manches Netherlands Foreign Investment Agency MEPC Milton Park UKTI Drug Discovery Today OBN VirdisPharma Interea International EBD Group EAPD Innovations Frank B Dehn TVLSN James Cowper Lab Support UK Ltd PULSE Scientific FOCUS Insurance Fry Heath Spence Oxford Science Park Mewburn Ellis LLP Riverbank IT Teva Pharmaceutical Industries

Click to View the 2008 Gallery

WHO SHOULD ATTEND?

Biotech & MedTech Executives

8 minute presentation opportunity to pharma and investor audience
Panel discussions for emerging biotechs on finance and key issues
Private 1-to-1 partnering rooms and booths

Mid & Large Pharma Executives

Access to Company presentations (Biotech and Medtech)
Private 1-to-1 partnering rooms and booths
Opportunity for dedicated partnering rooms

Investors

Invitation-only investor dinner
Wide range of investment opportunities
Private 1-to-1 partnering rooms
Opportunity for dedicated partnering rooms

Registration Fees

OBN Member companies can take advantage of the lower rate of �399 + VAT, including a complimentary ticket with the first person registering from within Full Member companies. Do consider registering early to ensure your partnering profile is available when partnering begins on February 17th 2009, before New Year's schedule kicks in.

Are you ready to join the 300+ companies expected at BioTrinity 2009?

Early Bird Registration Fee (until Dec 15, 2008)

Special Registration Fee (until Feb 14, 2009)

Registration Fee (until April 1, 2009)

On-site Registration Fee

�499 + VAT

�549 + VAT

�599 + VAT

�650 + VAT